Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis

• Published in: Modern rheumatology Vol. 31; no. 6; pp. 1135 - 1141
• Main Authors: Rongyi, Chen, Zongfei, Ji, Jiang, Lin, Sifan, Wu, Lingying, Ma, Ying, Sun, Wenshu, Yu, Xiaomeng, Cui, Xiufang, Kong, Xiaomin, Dai, Lili, Ma, Yanshan, Li, Lindi, Jiang
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02-11-2021
• Subjects: Angiographic progression; Angiography; Blood Sedimentation; Humans; hydroxychloroquine; Hydroxychloroquine - therapeutic use; inflammation; Longitudinal Studies; Retrospective Studies; Takayasu arteritis; Takayasu Arteritis - diagnostic imaging; Takayasu Arteritis - drug therapy; Angiographic progression; Takayasu arteritis; hydroxychloroquine; inflammation
• ISSN: 1439-7595; 1439-7609
• DOI: 10.1080/14397595.2021.1879347

Hydroxychloroquine (HCQ), an anti-malarial drug, is widely used in the treatment of rheumatic diseases. However, the benefits of HCQ in the treatment of Takayasu arteritis (TA) remain unclear, especially in terms of alleviation of vascular progression.
This longitudinal observational retrospective study was based on the East China TA cohort. Patients received routine treatment with prednisone and immunosuppressants. Fifty TA patients who underwent magnetic resonance angiography two times within a 1.5-year follow-up period of monitoring vascular changes were divided into HCQ and non-HCQ groups according to whether HCQ was prescribed. Changes in angiographic features were compared. Multivariate Cox regression analysis was employed to further validate the results.
Of 50 TA patients, 21 were prescribed HCQ. The two groups shared a similar disease course, vascular types, prednisone with immunosuppressants intervention strategy, globin level, and disease remission rate at 6 months. The HCQ group showed greater reduction in the inflammatory indices erythrocyte sedimentation rate and C-reactive protein (CRP) level (p < .05), and a significantly lower incidence of angiographic progression than the non-HCQ group (19.0% vs. 51.7%, p = .035). After adjustment for age and usage of tocilizumab, angiographic progression was found to be independently associated with CRP (hazard ratio [95% confidence interval], HR [95% CI]: 1.102 [1.000-1.024], p = .046), and the usage of HCQ (HR [95% CI]: 0.266 [0.075-0.940], p = .040).
HCQ enhanced the anti-inflammatory effect of routine treatment strategies with prednisone and immunosuppressants, and alleviated angiographic progression in TA.